Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 9/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381901 | 0.89 | METAP2 (0.42) | METAP2NPSR1LRRK2TP53LMNA | |
| SCHEMBL5372169 | 0.87 | METAP2 (0.41) | METAP2NPSR1TP53LMNASMN1; SMN2 | |
| SCHEMBL5371992 | 0.86 | ALDH1A1 (0.45) | METAP2NPSR1PKMLRRK2POLB | |
| SCHEMBL5385605 | 0.86 | METAP2 (0.47) | METAP2POLB | |
| SCHEMBL5378866 | 0.84 | GAA (0.43) | METAP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL5376845 | 0.82 | METAP2 (0.48) | METAP2NPSR1LMNASMN1; SMN2NPC1 | |
| SCHEMBL5380332 | 0.82 | METAP2 (0.42) | METAP2POLBTP53LMNASMN1; SMN2 | |
| SCHEMBL7089232 | 0.81 | PKM (0.42) | METAP2NPSR1PKMLRRK2POLB | |
| SCHEMBL5387206 | 0.81 | METAP2 (0.41) | METAP2NPSR1LRRK2LMNASMN1; SMN2 | |
| SCHEMBL5372059 | 0.81 | NFKB1 (0.44) | POLBTP53LMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885NPSR1 2820/4885PKM 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.